SG Americas Securities LLC Invests $125,000 in Global Blood Therapeutics Inc (NASDAQ:GBT)

Share on StockTwits

SG Americas Securities LLC purchased a new position in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,569 shares of the company’s stock, valued at approximately $125,000.

Several other large investors have also modified their holdings of the company. Quest Capital Management Inc. ADV bought a new position in Global Blood Therapeutics during the third quarter worth $26,000. Steward Partners Investment Advisory LLC bought a new stake in Global Blood Therapeutics in the second quarter valued at $27,000. Lindbrook Capital LLC increased its stake in Global Blood Therapeutics by 133.3% in the third quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock valued at $34,000 after purchasing an additional 400 shares in the last quarter. Captrust Financial Advisors bought a new stake in Global Blood Therapeutics in the second quarter valued at $42,000. Finally, Truvestments Capital LLC increased its stake in Global Blood Therapeutics by 48.0% in the third quarter. Truvestments Capital LLC now owns 925 shares of the company’s stock valued at $45,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 98.78% of the company’s stock.

NASDAQ:GBT opened at $66.50 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 14.95 and a quick ratio of 14.95. The firm has a 50-day moving average of $51.24 and a 200-day moving average of $53.21. Global Blood Therapeutics Inc has a one year low of $30.15 and a one year high of $71.94.

Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Thursday, November 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the prior year, the company earned ($0.83) EPS. As a group, sell-side analysts expect that Global Blood Therapeutics Inc will post -4.16 EPS for the current year.

Several equities research analysts have weighed in on GBT shares. Piper Jaffray Companies lifted their price target on shares of Global Blood Therapeutics from $80.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. BidaskClub raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. SunTrust Banks lifted their price target on shares of Global Blood Therapeutics to $110.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Morgan Stanley set a $60.00 price target on shares of Global Blood Therapeutics and gave the company a “hold” rating in a research note on Friday, August 9th. Finally, Nomura lifted their price target on shares of Global Blood Therapeutics from $109.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Global Blood Therapeutics currently has an average rating of “Buy” and a consensus target price of $91.44.

In related news, insider Joshua Lehrer-Graiwer sold 11,593 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $67.19, for a total transaction of $778,933.67. Following the transaction, the insider now directly owns 312 shares in the company, valued at $20,963.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Deval L. Patrick sold 5,357 shares of the business’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $45.05, for a total transaction of $241,332.85. Following the transaction, the director now owns 5,357 shares in the company, valued at $241,332.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,182 shares of company stock worth $1,867,355. 4.30% of the stock is owned by corporate insiders.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Recommended Story: What does a bar chart mean for investors?

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.